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ABSTRACT 
 
Background 
Whilst arthritis in other affected joints and back pain is known to lead to worse outcomes 
following total hip replacement surgery, these risk factors have not previously been 
operationalized as a musculoskeletal morbidity profile. The aim of this study was to measure 
the influence of other joints and spine (as grades of musculoskeletal morbidity) on the 1-year 
outcome of primary total hip replacement. 
 
Methods 
The European Collaborative Database of Cost and Practice Patterns of Total Hip 
Replacement study consists of 1,327 patients receiving primary THR for osteoarthritis across 
20 European orthopedic centers. The primary outcome was the responder rate for THR at 
12-months as measured by the relative effect per patient (REPP score), calculated for each 
patient using the total WOMAC score. The primary predictor of interest was combinations of 
arthritis of large joints and spine grouped into four musculoskeletal morbidity (MSM) grades: 
1 (single-joint), 2 (multi-joints), 3 (single-joint and spine), 4 (multi-joints and spine). 
Confounders adjusted for were: age, sex, body mass index, living alone, years of hip pain, 
ASA grade, anxiety/depression, pre-operative WOMAC subscales. 
 
Results 
845 patients were included for this analysis with complete 12-month follow-up WOMAC 
scores. The mean age was 65.7 years and 55.2% were female. Increasing MSM grade was 
associated with worse outcomes of surgery, where the proportion of patients responding 
to THR were: 254 (92.4%) MSM grade 1, 272 (87.2%) MSM grade 2, 46 (80.7%) MSM grade 
3, 142 (74.4%) MSM grade 4. This was confirmed in adjusted logistic regression models: 
MSM grade 4 vs. 1 relative risk ratio (RRR) 0.82 95% confidence interval (CI) (0.75, 0.90); 
MSM grade 3 vs. 1 OR 0.87 95%CI (0.77, 0.99); MSM grade 2 vs. 1 OR 0.95 95%CI (0.89, 
1.00).  
 
Conclusions 
Other joints and spine measured as musculoskeletal morbidity have a strong influence on the 
1-year outcome after THR.  The effect size was large in comparison to other risk factors. 
Even so, the majority of patients in MSM grade 4 can still profit from surgery (>75% 
response to surgery). 
 
Level of evidence 
Prognostic Study (Level II)   
 
  
  
INTRODUCTION 
Even if primary total hip replacement (THR) might be considered today as “standardized” surgery the 
outcome varies from patients with no more symptoms and/or disability after THR, to those with 
some symptoms/disability left, to those with even more symptoms and/or disability. This variation 
corresponds to the average WOMAC score in EUROHIP a year after THR not being zero but 15% or a 
responder rate not being 100% but 84.5%. Other studies confirm this variation with responder rates 
for primary THR from 84% to 93%1-5. Predictors for worse outcome are higher age, low 
symptom/disability score, high body mass index, number of general comorbidities, musculoskeletal 
morbidity and depression3, 4, 6-17.  
Although it is well known, that musculoskeletal comorbidity can have a negative impact on the 
overall outcome6, 11, 14, it is still not clear how big its influence is.  Hawker found a prevalence of 
troublesome other large joints (contralateral hip, knees) of 81.2% in a cohort with hip osteoarthritis 
coming for THR and only half of these patients achieved a good outcome11. Quintana described in a 
large multicenter study for THR a high prevalence of contralateral hip osteoarthritis (42.9%) and back 
pain (54.5%) separately with less improvement on some of the SF-36 and WOMAC domains 6 months 
after THR14. Ayers found coexisting pain in the lumbar spine and other nonoperatively treated joints 
to be an important confounder for outcome after joint replacement for the knee and described the 
need for a Musculoskeletal Comorbidity Index18.    
There is a limited number of possibilities to grade the severity of musculoskeletal comorbidities 
focusing on functional limitations as proposed by Charnley and Katz19, 20. Charnley differentiated the 
patients coming for THR in three groups depending on factors which limit the walking capacity (group 
A one hip involved, B both hips involved and C other factors). Katz et al. proposed a score of 
musculoskeletal functional limitations as the sum of limitations in 6 anatomic regions separately 
(knee, hip, back, hand/wrist/arm/shoulders, foot/ankle, neck). Both approaches to grade functional 
limitations and the status of affected joints were not included. 
The objective of this study was to measure the influence of other joints and spine (as grade of 
musculoskeletal morbidity (MSM)) on the outcome 1 year after THR in a large European multicenter 
cohort (EUROHIP). The null hypothesis was that MSM does not influence THR outcome.  
 
MATERIALS AND METHODS 
STUDY DESIGN 
Observational prospective cohort study 
Level of Evidence: II (prospective outcome study) 
 
SETTING AND SOURCE OF DATA 
The EUROHIP study comprised of 1,327 patients receiving primary THR across 20 European 
orthopedic centers in 12 nations21. It began collecting data in January 2004 and concluded December 
2006.  Inclusion criteria were a diagnosis of primary hip osteoarthritis (OA), primary THR, and a 
signed informed consent. Primary osteoarthritis of the hip was defined as symptomatic hip disease 
with radiographic evidence of osteoarthritis, and no obvious predisposing cause such as 
unequivocal dysplasia, congenital dislocation of the hip, Perthe’s disease or osteonecrosis. 
Exclusion criteria comprised severe mental illness or dementia, and patient’s unwillingness/inability 
to participate, and unequivocal evidence for secondary osteoarthritis. Each center was responsible 
for local ethical approval. The study protocol and data collection forms were designed in Bristol, UK 
and Ulm, Germany by the study principle investigators (PD and KD) and the study coordinator (SW). 
The patient questionnaire was reviewed for acceptability in Bristol and modified accordingly before 
being sent to Ulm for translation and distribution. Questionnaires were sent to each center for 
translation and returned for editing before printing and distribution with a set of instructions. 845 
patients were included in this study with a complete follow up of Patient Reported Outcome 
Measures (WOMAC) pre-THR and one year postoperatively (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Study flow chart (EUROHIP) 
 OUTCOME 
Patients completed a WOMAC questionnaire prior to surgery and at 12-months follow up22. This 
consists of 24 items in 3 subscales: pain (5), stiffness (2), and physical function (17).  For each 
subscale a normalized score was created (0 indicating no symptoms, 100 extreme symptoms) by 
summing up the total score of each subscale, multiplying it by 100, and dividing by the maximum 
score. A total score out of 96 was created by combining the 3 subscales, then converted into a 
normalized score. 
The relative effect per patient (REPP = (pretreatment score – post treatment score)/pre treatment 
score)2, 23 was calculated for each patient using the total WOMAC score.  A REPP of 1 (best score) 
corresponds to a patient without symptoms/disability after treatment, a REPP of 0.5 to 50% 
reduction, a negative REPP to more symptoms/disability in the follow up, -0.5 to an augmentation of 
50%. 
MAIN PREDICTOR 
The primary predictor of interest was the influence of other joints and spine. Prior to surgery patients 
were asked whether they had arthritis in any other parts of their body including large joints 
(shoulder, elbow or hand; other hip; knee; ankle or foot) and spine (neck; lower back). All the 
patients can be differentiated into four grades of musculoskeletal morbidity (Table 1). MSM grade 1: 
single-joint (only index hip joint); MSM grade 2: multi-joints (index hip joint and one or more other 
large joints); MSM grade 3: single-joint (index hip joint) and spine; MSM grade 4: multi-joints (index 
hip joint and one or more other large joints and spine). 
Table 1. Description of Musculoskeletal morbidity (MSM) grades and proportions 
 Without Spine With Spine 
Index Joint Grade 1  Grade 3 
 416 (32.1%) 112 (8.6%) 
Index & Other large joints Grade 2 Grade 4 
 479 (36.9%) 291 (22.4%) 
 
CONFOUNDERS 
Prior to surgery patients completed questionnaires including a wide range of demographic 
information. Demographic information considered relevant in this study included: age, sex, body 
mass index (BMI), whether or not they live alone or with someone else, the number of years they 
have had hip pain. Surgical teams recorded information on patient’s ASA grade (scored from 1 
(normal, healthy) to 4 (life-threatening systemic disease). Information on Anxiety/Depression was 
taken from the EQ5D questionnaire subscale. Pre-operative WOMAC subscales of pain, stiffness and 
function were included as further potential confounders. 
STATISTICAL METHODS 
Descriptive statistics (mean, standard deviation for continuous variables and number, percentage for 
categorical) were used to describe the characteristics of patients within the four MSM groups. A Box-
Whisker plot was used to graphically describe the overall REPP score within each of the four MSM 
groups. 
Logistic regression modeling was used to describe the association of the main predictor (MSM 
groups) with the outcome of interest (responder according to REPP score), controlling for 
confounding variables. Results of the regression model are presented as relative risk ratios by 
fitting a generalized linear model with a binomial error structure and a log link function (log-logistic 
model). Fractional polynomial regression was used to assess evidence of linearity of continuous 
predictors with the outcome. Multiple imputation by chained equations was used to account for the 
cumulative effect of missing data in several of the variables24. Forty imputed datasets were 
generated using all potential factors (including the outcome) and estimated parameters were 
combined using Rubin’s rules. 
Source of funding 
NIHR Musculoskeletal Biomedical Research Unit, University of Oxford. 
 
RESULTS 
 
Table 2. Descriptive characteristics and comparison of patients with complete follow-up and baseline 
assessment   
Variable Missing All patients (n=1327) 
Complete 
follow-up 
(n=845) 
Baseline (n=482) 
MSM grades: 29 (2.2%)       
    MSM grade 1    416 (32.1%) 275 (32.9%) 141 (30.5%) 
    MSM grade 2   479 (36.9%) 312 (37.4%) 167 (36.1%) 
    MSM grade 3   112 (8.6%) 57 (6.8%) 55 (11.9%) 
    MSM grade 4   291 (22.4%) 191 (22.9%) 100 (21.6%) 
Age 29 (2.2%) 65.7 (10.9) 65.7 (10.6) 65.7 (11.3) 
Sex 60 (4.5%)       
    Male   559 (44.1%) 359 (44.8%) 200 (43.0%) 
    Female   708 (55.9%) 443 (55.2%) 265 (57.0%) 
BMI 102 (7.7%) 27.5 (4.4) 27.8 (4.4) 27.0 (4.3) 
Living alone 10 (0.8%)       
    Alone   341 (25.9%) 207 (24.6%) 134 (28.3%) 
    Spouse/partner   900 (68.3%) 591 (70.1%) 309 (65.2%) 
    Somebody else   76 (5.8%) 45 (5.3%) 31 (6.5%) 
Anxiety/Depression 76 (5.7%)       
    None   698 (55.8%) 500 (59.9%) 198 (47.6%) 
    Moderate   496 (39.7%) 309 (37.0%) 187 (45.0%) 
    Extreme   57 (4.6%) 26 (3.1%) 31 (7.5%) 
Years of hip pain 13 (1.0%)       
    <1 year   141 (10.7%) 84 (10.0%) 57 (12.0%) 
    1-2 years   374 (28.5%) 242 (28.8%) 132 (27.9%) 
    3-5 years   403 (30.7%) 255 (30.4%) 148 (31.2%) 
    5+years   396 (30.1%) 259 (30.8%) 137 (28.9%) 
ASA grade 152 (11.5%)       
    1   209 (17.8%) 117 (15.8%) 92 (21.1%) 
    2   719 (61.2%) 469 (63.5%) 250 (57.3%) 
    3 or 4   247 (21.0%) 153 (20.7%) 94 (21.6%) 
WOMAC Pain Pre-op 72 (5.4%) 55.4 (17.8) 54.2 (17.6) 57.9 (18.0) 
WOMAC Stiffness Pre-op 61 (4.6%) 60.5 (20.7) 60.5 (20.1) 60.5 (22.0) 
WOMAC Function Pre-op 74 (5.6%) 60.1 (16.7) 58.6 (16.5) 63.3 (16.8) 
 
The characteristics of patients that completed the 12-month follow-up questionnaire (n=845) were 
similar to those of patients in the whole sample (n=1327) (Table 2). Patients with only baseline 
assessment (n=482) (lost to follow-up) were more likely to be living alone and had higher levels of 
anxiety and depression. 
Of the 845 patients included for this analysis, the mean age was 65.7 years (range 26 to 92) and 
55.2% were female. A quarter of patients lived alone and 59.9% reported no symptoms of anxiety or 
depression. The majority of patients (90%) had symptoms of hip pain for more than a year prior to 
surgery, with 30.8% of these patients having symptoms for more than 5-years. For the pattern of 
MSM, 32.9% had hip OA in the index joint only (grade 1), 37.4% OA in multiple joints (grade 2), 6.8% 
hip OA in the index joint with spine OA (grade 3), and 22.9% OA in multiple joints in addition to spine 
OA (grade 4). 
Table 3. Characteristics of patient subgroups in the four MSM grades 
  MSM grade 1  MSM grade 2 MSM grade 3 MSM grade 4 
      
Age 64.9 (11.4) 64.9 (10.9) 66.8 (8.8) 67.6 (9.3) 
Sex     
    Male 127 (48.7%) 130 (43.6%) 25 (47.2%) 72 (40.0%) 
    Female 134 (51.3%) 168 (56.4%) 28 (52.8%) 108 (60.0%) 
BMI 27.5 (4.5) 28.2 (4.6) 26.3 (3.3) 27.8 (4.3) 
Living alone     
    Alone 59 (21.5%) 74 (23.7%) 12 (21.1%) 59 (31.1%) 
    Spouse/partner 201 (73.4%) 222 (71.2%) 44 (77.2%) 118 (62.1%) 
    Somebody else 14 (5.1%) 16 (5.1%) 1 (1.8%) 13 (6.8%) 
Anxiety/Depression     
    None 171 (63.1%) 187 (60.9%) 31 (55.4%) 106 (55.5%) 
    Moderate 94 (34.7%) 108 (35.2%) 23 (41.1%) 79 (41.4%) 
    Extreme 6 (2.2%) 12 (3.9%) 2 (3.6%) 6 (3.1%) 
Years of hip pain     
    <1 year 36 (13.1%) 31 (9.9%) 6 (10.5%) 11 (5.8%) 
    1-2 years 81 (29.5%) 96 (30.8%) 18 (31.6%) 46 (24.3%) 
    3-5 years 79 (28.7%) 85 (27.2%) 21 (36.8%) 67 (35.5%) 
    5+years 79 (28.7%) 100 (32.1%) 12 (21.1%) 65 (34.4%) 
ASA grade     
    1 47 (19.4%) 46 (17.1%) 10 (19.2%) 14 (8.3%) 
    2 166 (68.6%) 162 (60.2%) 31 (59.6%) 104 (61.9%) 
    3 or 4 29 (12.0%) 61 (22.7%) 11 (21.2%) 50 (29.8%) 
WOMAC Pain Pre-op 51.4 (18.2) 54.8 (17.3) 53.3 (16.0) 57.7 (17.3) 
WOMAC Stiffness Pre-op 58.1 (19.9) 62.2 (19.5) 60.3 (19.8) 61.2 (20.9) 
WOMAC Function Pre-op 55.6 (16.9) 59.2 (15.9) 59.2 (15.6) 62.1 (16.6) 
 
The characteristics of patients within each of the four MSM groups is described in table 3. Patients 
with spinal pathology were slightly older compared to those with OA in other joints, but overall the 
distribution of age was very similar across all morbidity groups (Figure 2). Patients with OA in 
multiple joints (MSM grade 2 and 4) were more likely to be female, live alone and have suffered with 
hip pain for a greater number of years prior to surgery. Anxiety and depression was more common in 
those with spinal OA (MSM grades 3 and 4). There were fewer patients with ASA grade 3 or 4 in 
group MSM grade 1 with hip OA only (12%) compared to those with spine and hip OA in multiple 
joints (30%). No differences were observed in pre-operative WOMAC subscales across the morbidity 
groupings.  
 
 
 
 
Figure 2.  Kernel density plot describing distribution of age within each MSM grade 
 Figure 3. Box-whisker plot describing REPP score with each MSM grade 
 
As the grade of MSM increases the outcome according to the REPP score declined (Figure 3). Those in 
MSM grade 1 had the best outcome compared with those in grade 4, the worst. 
Figure 4. Forest plot describing results of univariable and multivariable logistic regression models 
 Findings of the logistic regression model confirmed an important significant association of grade of 
MSM on patient outcomes of THR surgery. As the grade of MSM increased, patients were less likely 
to achieve a response to THR surgery. The proportion of patients responding to surgery was 75% in 
MSM grade 4 compared to 92% in MSM grade 1. This remained after adjusting for a wide range of 
confounding factors, where the risk of response was 18% lower in MSM grade 4 versus 1 (Relative 
Risk Ratio 0.82 95% CI (0.75 to 0.90) (Figure 4). Hence, the null hypothesis is rejected.  
 DISCUSSION 
The grade of musculoskeletal morbidity influences the outcome of THR; in this study, it had the 
highest odd’s ratios of all compared parameters. A strength of this study was the large number of 
participants, and generalizability with participants from 20 different centers across Europe, different 
cultural regions and eight languages. 
The model of four grades of MSM allows separating the “heterogeneous” cohort of patients with hip 
OA coming for THR in four “homogenous” groups including the index joint, considering the other 
joints and spine respectively not as comorbidity but as morbidity of a system of musculoskeletal 
system. This should allow the surgeon to better manage the patients’ expectations especially in 
patients with higher grades of MSM. In these cases the patients can present in the follow up after 
THR with symptoms deriving from other joints and/or spine respectively. To the authors it seems 
important to focus not only on the affected hip joint but also on the other joints and spine which 
can influence the outcome; So the THR can be considered as a part of the treatment of the 
musculoskeletal system. A failure to provide this perception to the patient is likely a key source of 
patient dissatisfaction. 
 This model covers all different situations of patients with hip OA coming for THR; from the “simple” 
case with only one hip affected to the complex case with multiple other large joints affected and 
spine pathology. This grading can also be applied for bilateral OA of the hip or other joints; for 
instance in bilateral hip osteoarthritis (MSM grade 2) or in patients with knee or shoulder 
osteoarthritis. The MSM grading system can equally be applied to patients with knee OA coming 
for knee replacement, and shoulder arthritis for shoulder replacement.  That would allow to 
separate these patient groups in 4 more homogeneous groups with respect to outcome. Especially 
in knee OA it is known and reported that it occurs most frequently bilateral (MSM grade 2) and 
rather rarely monolateral (MSM grade 1).  Although this would need to be tested in other external 
cohorts of patients, as our data here is only for those receiving hip replacement surgery. 
An unexpected finding, was the high prevalence of patients with MSM grades 2,3 and 4 of 68%; in 
other words only a third of the patients had just osteoarthritis of the index joint. A second 
unexpected finding was that there were no differences in the gender and age distribution of patients 
in each of the 4 MSM grades. From literature we expected a higher average age in the patient groups 
higher MSM grade >111. These findings need further research. 
Using the 4 MSM grades in daily practice allows to counsel the patients better preoperatively and to 
manage their expectations of outcome with higher precision. Even patients with hip OA and MSM 
grade 4 still profit from surgery with a responder rate of 75%, but the score after THR remains higher 
compared to MSM grade 1. In difficult, unclear situations, a test infiltration with local anesthetics of 
the affected hip may illustrate the potential effect of THR for the patient.  
Bellamy designed the WOMAC questionnaire to measure osteoarthritis of one hip or knee (MSM 
grade 1). One third of the patients fulfilled this criterion and were “properly” assessed22. Knowing 
this fact, we realized retrospectively that in two thirds of patients that the WOMAC is capturing 
additional symptoms/disability from other joints and/or spine. A basic difficulty might be the lack of 
localization of symptoms in the WOMAC. New patient questionnaires have integrated the 
localization of symptoms for the global patient as a whole e.g. Pationnaire, ICOAP (both mannequin 
based systems)25-28. 
In this study were different limitations: All participating centers had experience and interest in THR 
and so a positive selection bias of the included patients has to be supposed. This may lead to better 
results and a higher responder rate than in daily routine. A limitation of the study is that it is not 
possible to separate ipsilateral vs. contralateral pathologies. Another limitation is the problem of 
ipsilateral hip and knee arthritis, where the principal symptoms present in the thigh and it is a 
difficult situation to diagnose. There was no information about complications during the study/after 
THR and the further management of these patients. So it may be, that one clinic excluded these 
patients with no further follow up in the study or that they still were included without knowing about 
reduction or revision surgery. This influence remains unknown. The grading of MSM depended on an 
additional question tested and validated locally in Bristol by one coauthor (PD). The distributions of 
the MSM grades showed no substantial differences across the participating centers. 
CONCLUSIONS 
Arthritis in other large joints and spine measured as musculoskeletal morbidity has a strong influence 
on the 1-year outcome after THR.  In this study, compared to other risk factors (mental factors, low 
score, gender and age) it has the largest impact on outcome. The responder rates decline linearly 
with each MSM grade (MSM grade 1 (single-joint) > MSM grade 2 (multi-joints) > MSM grade 3 
(single-joint and spine) > MSM grade 4 (multi-joints and spine). The prevalence of MSM grades 2, 3 
and 4 in patients with osteoarthritis of one hip is higher than expected (68% of the cohort). Even 
patients in MSM grade 4 still profit from surgery (>75% responder rate). 
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